BPM31510IV is also a lead candidate to treat solid tumours such as glioblastoma multiforme and pancreatic cancer.

BPGbio received an FDA Rare Pediatric Disease Designation for its potential treatment for primary coenzyme Q10 deficiency.

BPGbio to present novel Huntington's Disease and Alzheimer's Disease research at the Society for Neuroscience 2024 annual meeting.

Boston, Massachusetts Tuesday, October 1, 2024, 14:00 Hrs [IST] ...

BOSTON–(BUSINESS WIRE)–#bpgbio—BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that the U.S. Food ...

Garmin Ltd. invites shareholders and investors to listen to its third quarter 2024 earnings conference call on Wednesday, October 30, 2024, at 10:30 a.m. EDT, with executives of Garmin. The call will ...

Respiratory syncytial virus, or RSV, is a common respiratory virus that can infect people of all ages. RSV is so common that nearly 100% of children have been infected with the virus by age two and it ...

BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, will present the results of two transformative studies at ...